MiR-504 and miR-205 May be Used to Evaluate Prognosis and Chemotherapeutic Effect of Pancreatic Cancer Patients

To explore the value of miR-504 and miR-205 in evaluating the prognosis and chemo-therapeutic effect of pancreatic cancer (PC) patients. Ninety-six PC patients who came to our hospital from March 2015 to February 2017 were selected as the research group (RG), and 96 healthy subjects during the same period were considered as the control group (CG). Serum miR-504 and miR-205 of subjects in the two groups were detected and compared by Rt-PCR, and the miR-504 and miR-205 expression levels in serum of PC patients before and after chemotherapy were analyzed, so did the relationship between miR-504, miR-205 and prognosis of patients. The miR-504 and miR-205 expression levels in serum of PC patients were dramatically higher than those of healthy people (P[ 0.05), and the expression levels in serum of those in the chemotherapy-effective group were dramatically lower than those of those in the chemotherapy-ineffective group (P[ 0.05). Moreover, the 3-year mortality of patients with high expression of miR-504 and miR-205 was higher than that of those with low expression (P[ 0.05), and the miR-504 and miR-205 expression levels in dead patients were higher than those in living patients. miR-504 and miR-205 had high predictive value for poor prognosis of PC patients. Univariate analysis identified that their poor prognosis was related to pathological stage, lymph node metastasis, differentiation degree and expression of miR-504 and miR-205 (P[ 0.05). Cox multivariate analysis identified that pathological stage, lymph node metastasis, differentiation degree and expression of miR-504 and miR-205 were independent risk factors for poor prognosis (P[ 0.05).DLX6-AS1 is highly expressed in the serum of PC patients, and it can evaluate the chemotherapeutic effect and predict the prognosis. So, it may be used as a new target direction for evaluating the chemotherapeutic effect and predicting the prognosis of patients.